FENNEC PHARMACEUTICALS INC. Accounts Payable
FENNEC PHARMACEUTICALS INC. (FENC) had Accounts Payable of $5.52 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $5.52M.
- 2026-03-31: Accounts Payable, Current $6.28M.
- 2025-12-31: Accounts Payable, Current $4.63M.
- 2025-09-30: Accounts Payable, Current $5.87M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $5.52M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $6.28M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.63M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $5.87M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $5.94M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $5.28M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.24M 10-K · filed 2026-03-27 |
| 2024-09-30 | $3.87M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $4.45M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $5.20M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.78M 10-K · filed 2025-03-26 |
| 2023-09-30 | $2.94M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $3.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.95M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $2.39M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.53M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.74M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.22M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $777.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.15M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $677.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $2.51M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.57M 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.68M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $2.75M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.68M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $1.61M 10-K · filed 2021-03-30 |
| 2019-09-30 | $788.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.23M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.30M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $1.03M 10-K · filed 2020-02-14 |
| 2018-09-30 | $1.87M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $709.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $1.03M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $855.00K 10-K · filed 2019-03-15 |
| 2017-09-30 | $492.00K 10-Q · filed 2017-11-13 |
| 2017-06-30 | $296.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $224.00K 10-Q · filed 2017-05-12 |
| 2016-12-31 | $244.00K 10-K · filed 2018-03-28 |
| 2016-09-30 | $235.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $345.00K 10-Q · filed 2016-08-12 |
| 2016-03-31 | $225.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $297.00K 10-K · filed 2017-03-29 |
| 2015-09-30 | $252.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $401.00K 10-Q · filed 2015-08-11 |
| 2015-03-31 | $384.00K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $308.00K 10-K · filed 2016-03-28 |
| 2014-09-30 | $364.00K 10-Q · filed 2014-11-13 |
| 2014-06-30 | $335.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $154.00K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $212.00K 10-K · filed 2015-03-31 |
| 2013-09-30 | $315.00K 10-Q · filed 2013-11-18 |
| 2013-06-30 | $716.00K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $698.00K 10-Q · filed 2013-05-13 |
| 2012-12-31 | $259.00K 10-K · filed 2014-03-31 |
| 2012-09-30 | $315.00K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $276.00K 10-Q · filed 2012-08-13 |
| 2012-03-31 | $374.00K 10-Q · filed 2012-05-15 |
| 2011-12-31 | $342.00K 10-K · filed 2013-04-01 |
| 2011-09-30 | $414.00K 10-Q · filed 2011-11-14 |
| 2011-06-30 | $239.00K 10-Q · filed 2011-08-15 |
| 2010-12-31 | $272.00K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |